Docs rate exhibits as better than ads

Share this article:
Physicians prefer exhibits at medical meetings to some other modes of learning about new drugs and technologies, a study suggests.

M|C Communications polled attendees at a Pri-Med meeting earlier this year—212 before and 182 after. The Healthcare Convention & Exhibitors Association presented the data in June.

Sixty-six percent favor getting information on new drugs from exhibitors, vs. 16% who prefer journal ads and 69% who prefer journal articles. For medical technology information, most clearly prefer exhibitors.

In addition, almost half said their offices restrict access by detailers or plan to within the next six months.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...